전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved14 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleSeagenvedotin and the anti-HER2 t…Preclinical

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

Untreated CD30-Positive Hodgkin's Lymphoma · Peripheral T Cell Lymphoma

#PeripheralTCellLymphoma#ADC#Preclinical#Popular#antibody-drug-conjugate+4
Trials 93Status Active
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#antibody-drug-conjugate#RefractoryPeripheralT-CellLympho+2
Trials 24Status Active
CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Peripheral T Cell Lymphoma · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 7Status Recruiting
AntibodyLimited DatastaleImmunoGen, Inc.Phase 2

Lorvotuzumab Mertansine (Lorvotuzumab Mertansine)

Pleuropulmonary Blastoma; Recurrent Malignant Peripheral Nerve Sheath Tumor · Pleuropulmonary Blastoma

#PleuropulmonaryBlastoma#Antibody#Phase2#monoclonal-antibody#RecurrentMalignantPeripheralNerv+1
Trials 7Status Active
CGTLimited DatastaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus chidamide (Consolidation therapy- 3 or 6 cycles of BvC, Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus Chidamide (Induction therapy-3 cycles of BvC, Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryPeripheralTC+2
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous CCR4 CAR T cells (Autologous CCR4 CAR T cells)

Relapsed and/or Refractory Mature T Cell Malignancy; Peripheral T-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPreclinical

brentuximab vedotin (Adcetris, Brentuximab Vedotin Plus CHP)

CD30-Positive Peripheral T-Cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30-PositivePeripheralT-CellLym+1
Trials 1Status Recruiting
CGTLimited DatastaleTessa TherapeuticsPhase 1

CD30 CAR-T (CD30 CAR-T)

Anaplastic Large Cell Lymphoma; Peripheral T Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Siplizumab (Siplizumab)

T-Cell Peripheral Lymphoma; Gamma Delta Hepatosplenic T-Cell Lymphoma · T-Cell Peripheral Lymphoma

#T-CellPeripheralLymphoma#Antibody#Phase1#monoclonal-antibody#GammaDeltaHepatosplenicT-CellLym+1
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

mCD19-CAR-CD28-CD3-zeta. (anti-CD19 CAR, mCD19-CAR-CD28-CD3-zeta., mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL))

Hematologic Malignancies; Hematologic Neoplasms · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

peripheral blood progenitor cells carrying MDR1 (peripheral blood progenitor cells carrying MDR1)

Breast Neoplasms; Neoplasm Metastasis · Breast Neoplasms

#BreastNeoplasms#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active